Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Age ≥ 18 years
Advanced or metastatic melanoma
Current treatment with nivolumab for advanced or metastatic melanoma, in a 6 mg/kg or 480 mg, 4 weekly scheme
Documented confirmed and ongoing CR, PR or SD according to RECIST v1.1
On treatment for at least 6 months

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response